Comparator: Placebo + Comparator: MK0724
Phase 2Terminated 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Middle Cerebral Artery Stroke
Conditions
Middle Cerebral Artery Stroke
Trial Timeline
Jul 1, 2007 → Jan 1, 2009
NCT ID
NCT00401310About Comparator: Placebo + Comparator: MK0724
Comparator: Placebo + Comparator: MK0724 is a phase 2 stage product being developed by Merck for Middle Cerebral Artery Stroke. The current trial status is terminated. This product is registered under clinical trial identifier NCT00401310. Target conditions include Middle Cerebral Artery Stroke.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00401310 | Phase 2 | Terminated |
Competing Products
3 competing products in Middle Cerebral Artery Stroke
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| recombinant human erythropoietin alfa + 0.9% NaCl | Johnson & Johnson | Phase 2/3 | 65 |
| Piracetam | UCB | Approved | 82 |
| INO-4700 + Placebo + INO-4700 | Inovio Pharmaceuticals | Phase 2 | 44 |